- Home
- WOLF vs SNDX Comparison
WOLF vs SNDX Comparison
Compare WOLF & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- SNDX
- Stock Information
- Founded
- WOLF 1987
- SNDX 2005
- Country
- WOLF United States
- SNDX United States
- Employees
- WOLF N/A
- SNDX N/A
- Industry
- WOLF Semiconductors
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- SNDX Health Care
- Exchange
- WOLF Nasdaq
- SNDX Nasdaq
- Market Cap
- WOLF 978.5M
- SNDX 1.1B
- IPO Year
- WOLF 1993
- SNDX 2016
- Fundamental
- Price
- WOLF $0.90
- SNDX $9.48
- Analyst Decision
- WOLF Hold
- SNDX Strong Buy
- Analyst Count
- WOLF 14
- SNDX 11
- Target Price
- WOLF $10.67
- SNDX $35.91
- AVG Volume (30 Days)
- WOLF 30.4M
- SNDX 1.8M
- Earning Date
- WOLF 05-08-2025
- SNDX 07-31-2025
- Dividend Yield
- WOLF N/A
- SNDX N/A
- EPS Growth
- WOLF N/A
- SNDX N/A
- EPS
- WOLF N/A
- SNDX N/A
- Revenue
- WOLF $761,300,000.00
- SNDX $43,722,000.00
- Revenue This Year
- WOLF N/A
- SNDX $426.77
- Revenue Next Year
- WOLF $11.97
- SNDX $98.31
- P/E Ratio
- WOLF N/A
- SNDX N/A
- Revenue Growth
- WOLF N/A
- SNDX N/A
- 52 Week Low
- WOLF $0.82
- SNDX $8.58
- 52 Week High
- WOLF $25.60
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- WOLF 31.20
- SNDX 36.85
- Support Level
- WOLF $0.83
- SNDX $11.00
- Resistance Level
- WOLF $1.53
- SNDX $11.83
- Average True Range (ATR)
- WOLF 0.21
- SNDX 0.58
- MACD
- WOLF 0.02
- SNDX -0.11
- Stochastic Oscillator
- WOLF 7.62
- SNDX 10.31
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.